Composition for on-demand ultrasound-triggered drug delivery

Patent metadata

Field	Value
Publication number	US-10010709-B2
Application number	US-201013515764-A
Country	US
Kind code	B2
Filing date	Dec 16, 2010
Priority date	Dec 16, 2009
Publication date	Jul 3, 2018
Grant date	Jul 3, 2018

Abstract

Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.

First claim

What is claimed is:

1. A composition implantable in living tissue as a drug depot for delivering a therapeutic agent to a targeted area of a subject to be treated over a period of time, the composition comprising:
a protective medium composed of a hydrogel and configured to degrade in response to application of ultrasound energy;
an agent encapsulated in an encapsulating material, the encapsulating material being suspended in the protective medium; and
a plurality of microbubbles suspended in the protective medium, each of the microbubbles having an envelope of material that is different from said protective medium and encapsulating a respective gas core, wherein
the composition is configured to permit the regulation of the release of the agent from the protective medium by selective application of the ultrasound energy to the protective medium,
the hydrogel is capable of maintaining the agent and the microbubbles in close proximity to each other,
the microbubbles are present at a concentration effective to disrupt the encapsulating material of the agent to release the agent into the protective medium, and
the protective medium is configured to permit the release of the agent from the protective medium by the selective application of the ultrasound energy.

2. The composition of claim 1 , wherein the release of the agent from the protective medium is triggered by exposure to a biocompatible dose of the ultrasound energy delivered to the targeted area.

3. The composition of claim 2 , wherein the rate of the release of the agent from the protective medium is responsive to a dose and a rate of the ultrasound energy applied thereto.

4. The composition of claim 3 , wherein the dose and the rate of agent release may be regulated responsively to a parameter of the applied ultrasound energy, the parameter including at least one of intensity, frequency and duration.

5. The composition of claim 4 , wherein the agent includes a pharmaceutical agent and/or a biologic agent.

6. The composition of claim 5 , wherein the degradation of the hydrogel changes according to changes in the intensity, frequency and duration of the applied ultrasound energy.

7. The composition of claim 6 , wherein the encapsulating material is one of a lipid vesicle, a microparticle, a nanoparticle, and a particle having a diameter greater than 500 microns.

8. The composition of claim 2 , wherein the release of agent may be induced by the application of biocompatible amounts of the ultrasound energy by means of a plurality of transducers focused at a target area where the protective medium is located in a living host without injuring the living tissue of the living host.

9. The composition of claim 1 , wherein the envelope of each microbubble is a lipid monolayer structure.

10. The composition of claim 1 , wherein the envelope of each microbubble is a lipid bilayer structure.

11. The composition of claim 1 , wherein the encapsulating material is of a substance that is different from the protective medium.

12. The composition of claim 1 , wherein said agent includes a therapeutic substance.

13. The composition of claim 1 , wherein said agent includes a drug.

14. The composition of claim 1 , wherein said agent includes a diagnostic substance.

Assignees

• Kohane Daniel S
• Epstein Barash Hila
• Borden Mark A
• Univ Columbia
• Massachusetts Inst Technology
• Childrens Medical Center

Inventors

• Kohane Daniel S
• Epstein-Barash Hila
• Borden Mark A

Classifications

• A61M37/0069 Primary

  Devices for implanting pellets, e.g. markers or solid medicaments (for introducing of radioactive sources for interstitial radiation therapy, i.e. brachytherapy A61N5/1027) · CPC title

• A61K41/0028

  Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds · CPC title

• A61K9/0009

  involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis · CPC title

• A61L2300/626

  Liposomes, micelles, vesicles · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title